Clinical trials: Pancreatic Metastatic Cancer
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Pancreatic Neoplasms, Neoplasm Metastasis
Hepatic Resection for Metastatic Pancreatic Cancer
The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM).
- Conditions
- Pancreatic Neoplasms, Neoplasm Metastasis, Liver Metastases
- Trial name
- NCT02892305
- Testing
- Hepatic Resection or Ablation with Pancreaticoduodenectomy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Locally Advanced or Metastatic Solid Tumours
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT04999969
- Testing
- AZD0171, Durvalumab, Gemcitabine
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- AstraZeneca
Cervical Cancer, Pancreatic Cancer
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the…
- Conditions
- Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma
- Trial name
- NCT01583686
- Testing
- Fludarabine, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL), Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT05605522
- Testing
- [225]-FPI-2059, [111In]-FPI-2058
- Where
- 8 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- 3B Pharmaceuticals GmbH
Metastatic Pancreatic Adenocarcinoma
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after…
- Trial name
- GEMPAX (NCT03943667)
- Testing
- Gemcitabine, Paclitaxel
- Where
- 26 sites in France
- Volunteers
- 211 people
- Sponsor
- UNICANCER
Metastatic Pancreatic Cancer
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
- Trial name
- NCT00837031
- Testing
- Lenalidomide, Gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic PDAC, HER2-positive Status
A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy
Pancreatic cancer is an extremely high-mortality malignancy. The chemotherapy regimen of gemcitabine combined with nab-paclitaxel (GEM-NABP) serves as one of the first-line standard therapies for metastatic pancreatic cancer.
- Trial name
- NCT07176702
- Testing
- HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe…
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Trial name
- PANGEA (NCT06483555)
- Testing
- Gemcitabine, Nab paclitaxel, Erlotinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Pancreatic Carcinoma
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
This is a phase I clinical trial examining the safety, feasibility, and toxicity of gemcitabine and erlotinib when given in combination with capecitabine in adult patients with locally advanced unresectable or metastatic…
- Trial name
- NCT00480584
- Testing
- gemcitabine, capecitabine, erlotinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer
This is multicenter, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Primary objective: objective response rate.
- Trial name
- SPaCe-01 (NCT00536614)
- Testing
- cetuximab
- Where
- 10 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Second-line therapy with Nal-IRI after failure gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
- Trial name
- PREDICT (NCT03468335)
- Testing
- Irinotecan Liposomal Injection [Onivyde]
- Where
- 35 sites in Germany
- Volunteers
- 151 people
- Sponsor
- AIO-Studien-gGmbH
Metastatic Cancer
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.
- Trial name
- MODULATE (NCT03009058)
- Testing
- IMM-101, Gemcitabine, Nab-paclitaxel
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Immodulon Therapeutics Ltd
Metastatic Pancreatic Cancer
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
- Trial name
- BrUOG-PA205 (NCT00439179)
- Testing
- cohort 1, cohort 2, cohort 3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Brown University
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Neoplasms
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countries.
- Trial name
- NCT02043288
- Testing
- NC-6004, Gemcitabine
- Where
- 43 sites in Hong Kong, Japan and 5 more
- Volunteers
- 310 people
- Sponsor
- Orient Europharma Co., Ltd.
Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective in slowing tumor activity in participants with locally advanced or metastatic pancreatic cancer who have not had chemotherapy.
- Trial name
- NCT00651742
- Testing
- S-1
- Volunteers
- 28 people
- Sponsor
- Taiho Oncology, Inc.
Pancreatic Cancer
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic pancreatic cancer.
- Trial name
- NCT00925769
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], erlotinib [Tarceva]
- Where
- 2 sites in Austria
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Metastatic Pancreatic Ductal Adenocarcinoma
Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer
This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.
- Trial name
- NCT04631445
- Testing
- Ketogenic Diet
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Translational Drug Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.